Cirrhosis News and Research

Latest Cirrhosis News and Research

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Study suggests curcumin may be an effective therapy for liver fibrosis

Curcumin, a chemical that gives curry its zing, holds promise in preventing or treating liver damage from an advanced form of a condition known as fatty liver disease, new Saint Louis University research suggests.

30 Oct 2010

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.

25 Oct 2010

Childhood cancer survivors at increased risk of gastrointestinal problems

People treated for cancer when they were children have a higher-than-average risk of gastrointestinal problems - some mild, some quite severe - in the years following treatment, according to a study to be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Sunday, Oct. 24.

25 Oct 2010

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Research conducted by scientists at LSU Health Sciences Center New Orleans has found that two proteins in the brain act as valves to turn the hormone that regulates water retention in the body on and off. Their findings may lead to advances in treatment for diseases like high blood pressure, congestive heart failure, and cirrhosis of the liver. The research is published in the November 1, 2010 issue of Endocrinology.

25 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

20 Oct 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

An overview on American College of Gastroenterology's Annual Scientific meeting

The association between obesity and gastrointestinal-related cancers and coronary artery disease; the link between an overweight or obese body mass index and the severity of Crohn's disease; and whether inflammatory bowel disease is an independent risk factor for coronary artery disease, were among the highlights of new research that was presented this week at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio.

19 Oct 2010

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Estimates of the prevalence of liver disease suggest that one‐third of the United States population has non‐alcoholic fatty liver disease (NAFLD). NAFLD is now the most common cause for elevated liver function tests in the United States, a trend related to the obesity epidemic in this country. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis and all its complications.

19 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

MRI-guided laser ablation offers way to kill tumors

Physicians at Mayo Clinic's Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Research reveals new details about health benefits of fish-oil

Some of America's most popular fish salmon and albacore tuna, for example are rich in healthful natural compounds known as omega-3 fatty acids. Ongoing studies by U.S. Department of Agriculture (USDA) chemist Darshan S. Kelley and co-investigators are helping uncover new details about how these fish-oil components help protect us from chronic diseases.

12 Oct 2010

Study shows radioembolisation with TheraSphere effective for primary liver cancer

MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.

7 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

AASLD, TFAH report calls for action to help identify Americans living with HBV, HCV

The American Association for the Study of Liver Diseases and the Trust for America's Health issued a new report today calling for action to be taken to transform how the country deals with viral hepatitis – to help identify millions of Americans who know they are living with chronic forms of hepatitis B and C and to assure access to treatment for all who need it, to prevent even more Americans from becoming infected.

28 Sep 2010

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

23 Sep 2010

Cirrhosis News and Research

Latest Cirrhosis News and Research

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Study suggests curcumin may be an effective therapy for liver fibrosis

Sandoz initiates voluntary recall of Methotrexate Injection

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

Childhood cancer survivors at increased risk of gastrointestinal problems

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

An overview on American College of Gastroenterology's Annual Scientific meeting

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

MRI-guided laser ablation offers way to kill tumors

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

Research reveals new details about health benefits of fish-oil

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

AASLD, TFAH report calls for action to help identify Americans living with HBV, HCV

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cirrhosis News and Research

Latest Cirrhosis News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in